Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy

FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease

U.S. Food and Drug Administration grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253

Multitude Therapeutics’ AMT-676 receives Breakthrough Therapy Designation from China’s CDE

TQB2102 receives BTD from the CDE for patients with unresectable or metastatic HER2-low Breast cancer

U.S. FDA grants Orphan Drug Designation to Zai Lab’s DLL3-targeting ADC Zocilurtatug pelitecan for the...